CodeSystem |
http://fhir.org/guides/cdc/opioid-mme-r4/CodeSystem/CDCMMEClinicalConversionFactors  | CDC MME Clinical Conversion Factors |
http://fhir.org/guides/cdc/opioid-mme-r4/CodeSystem/cfct-example-CDCMMEClinicalConversionFactors  | Example CDC MME Clinical Conversion Factors |
http://profiles.ihe.net/PCC/RIPT/StructureDefinition/IHE.PCC.RIPT.Mediaction  | RIPT Mediaction |
http://hl7.org/fhir/uv/vulcan-rwd/ValueSet/ExampleClopidogrelCodes  | ACS Example Clopidogrel Codes |
http://hl7.org/fhir/uv/vulcan-rwd/ValueSet/ExamplePrasugrelCodes  | ACS Example Prasugrel Codes |
http://hl7.org/fhir/uv/vulcan-rwd/ValueSet/ExampleTicagrelorCodes  | ACS Example Ticagrelor Codes |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-aldosterone  | Aldosterone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-aspirin  | Aspirin Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-betamethasone-exclude  | Exclude Betamethasone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-betamethasone  | Betamethasone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-bromfenac-exclude  | Exclude Bromfenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-bromfenac  | Bromfenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-bumetanide  | Bumetanide Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-celecoxib  | Celecoxib Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-cloprednol  | Cloprednol Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-cortisone  | Cortisone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-cortivazol  | Cortivazol Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-cyclosporine-exclude  | Exclude cyclosporine Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-cyclosporine  | Cyclosporine Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-deflazacort  | Deflazacort Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-desoxycorticosterone  | Desoxycorticosterone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-dexamethasone-exclude  | Exclude Dexamethasone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-dexamethasone  | Dexamethasone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-dexlansoprazole  | Dexlansoprazole Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-diclofenac-exclude  | Exclude Diclofenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-diclofenac  | Diclofenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-diflunisal  | Diflunisal Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-digoxin  | Digoxin Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-eplerenone  | Eplerenone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-esomeprazole  | Esomeprazole Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ethacrynate  | Ethacrynate Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-etodolac  | Etodolac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-fenoprofen  | Fenoprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-fludrocortisone  | Fludrocortisone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-fluocortolone-exclude  | Exclude Fluocortolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-fluocortolone  | Fluocortolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-flurbiprofen-exclude  | Exclude Flurbiprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-flurbiprofen  | Flurbiprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-furosemide  | Furosemide Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-hydrocortisone-exclude  | Exclude Hydrocortisone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-hydrocortisone  | Hydrocortisone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ibuprofen-exclude  | Exclude Ibuprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ibuprofen  | Ibuprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-indomethacin  | Indomethacin Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ketoprofen-exclude  | Exclude Ketoprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ketoprofen  | Ketoprofen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ketorolac-exclude  | Exclude Ketorolac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-ketorolac  | Ketorolac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-lansoprazole  | Lansoprazole Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-mefenamate  | Mefenamate Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-meloxicam  | Meloxicam Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-meprednisone  | Meprednisone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-methylprednisolone-exclude  | Exclude Methylprednisolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-methylprednisolone  | Methylprednisolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-misoprostol  | Misoprostol Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-nabumetone  | Nabumetone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-naproxen  | Naproxen Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-nepafenac-exclude  | Exclude Nepafenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-nepafenac  | Nepafenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-omeprazole  | Omeprazole Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-oxaprozin  | Oxaprozin Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-pantoprazole  | Pantoprazole Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-paramethasone  | Paramethasone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-piroxicam-exclude  | Exclude Piroxicam Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-piroxicam  | Piroxicam Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-prednisolone-exclude  | Exclude Prednisolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-prednisolone  | Prednisolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-prednisone  | Prednisone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-prednylidene  | Prednylidene Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rabeprazole  | Rabeprazole Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone-exclude  | Exclude Rimexolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone  | Rimexolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-spironolactone  | Spironolactone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-sulindac  | Sulindac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-tolmetin  | Tolmetin Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-topicaldiclofenac  | Topical Diclofenac Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-torsemide  | Torsemide Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-triamcinolone-exclude  | Exclude Triamcinolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-triamcinolone  | Triamcinolone Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-trilostane  | Trilostane Medications Value Set |
http://hl7.org/fhir/uv/pddi/ValueSet/valueset-warfarin  | Warfarin Medications Value Set |
http://terminology.hl7.org/ValueSet/v3-KnowledgeSubjectObservationValue  | KnowledgeSubjectObservationValue |
http://cqframework.org/cpg-example-opioids/ValueSet/opioids-with-ambulatory-abuse-potential  | Opioids with Ambulatory Abuse Potential |
http://hl7.org/fhir/uv/ips/ValueSet/medication-example-uv-ips  | Medications - example (IPS) |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/amphetamines-class-medications  | Amphetamine class medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/benzodiazepine-medications  | Benzodiazepine medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/buprenorphine-and-methadone-medications  | Buprenorphine and Methadone medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/cns-depressant-medications  | CNS depressant medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/extended-release-opioid-with-ambulatory-misuse-potential  | Extended release opioid with ambulatory misuse potential |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/fentanyl-type-medications  | Fentanyl-type medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/methadone-medications  | Methadone medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/naloxone-medications  | Naloxone medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/non-opioid-cns-depressant-medications  | Ambulatory setting non-opioid CNS depressant medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/non-synthetic-opioid-medications  | Non-synthetic opioid medications |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/opioid-analgesics-with-ambulatory-misuse-potential  | Opioid analgesics with ambulatory misuse potential |
http://fhir.org/guides/cdc/opioid-cds/ValueSet/synthetic-opioid-medications  | Synthetic opioid medications |
http://hl7.org/fhir/us/davinci-drug-formulary/ValueSet/NonPackSemanticDrugVS  | Non-Pack Semantic Drug Codes |
http://hl7.org/fhir/us/davinci-drug-formulary/ValueSet/SemanticDrugFormGroupVS  | Semantic Drug Form Group Codes |
http://hl7.org/fhir/us/davinci-drug-formulary/ValueSet/SemanticDrugVS  | Semantic Drug Codes |
http://hl7.org/fhir/us/registry-protocols/ValueSet/Antiarrhythmics  | All Antiarrhythmics |
https://twcore.mohw.gov.tw/ig/twcore/ValueSet/medication-rxnorm-tw  | RxNorm藥品代碼值集 |
http://hl7.org/fhir/ValueSet/dataelement-sdcobjectclass  | DataElement SDC Object Class |
http://hl7.org/fhir/ValueSet/dataelement-sdcobjectclassproperty  | DataElement SDC Object Class Property |
http://hl7.org/fhir/uv/saner/ValueSet/Remdesivir  | Remdesivir |
http://fkcfhir.org/fhir/ValueSet/fmc-allergy-code-vs  | Fresenius Allergy Code Value Set |
http://fkcfhir.org/fhir/ValueSet/fmc-medication-code-vs  | Fresenius Medication Code Value Set |
http://moh.gov.vn/fhir/core/ValueSet/vn-medication-code  | ValueSet dành cho Mã dược phẩm |
http://fhir.health.gov.il/ValueSet/il-core-medication-code  | ILCore Medication Code |
http://dicom.nema.org/medical/dicom/current/output/chtml/part16/sect_CID_12.html  | ImagingContrastAgent |
http://dicom.nema.org/medical/dicom/current/output/chtml/part16/sect_CID_3850.html  | ContrastBolusSubstance |
http://terminology.hl7.org/ValueSet/v3-KnowledgeSubjectObservationValue  | KnowledgeSubjectObservationValue |
http://hl7.org/fhir/us/carin-rtpbc/ValueSet/rtpbc-prescribable-product-code  | RTPBC Prescribable Product Code Value Set |
http://phinvads.cdc.gov/fhir/ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.13.8.144  | Fertility Enhancing Drugs (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.13.8.23  | Augmentation of Labor - Medication (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.13.8.26  | Epidural Anesthesia - Medication (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.13.8.28  | Spinal Anesthesia - Medication (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.13.8.3  | Antibiotics (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.13.8.38  | Glucocortico Steroids (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.16  | Medication Brand Name Value Set |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1103  | Semantic Clinical Drug (Ingredient plus strength and dose form) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1104  | Semantic Clinical Drug Form (Ingredient plus dose form) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3120  | Antibiotic Received (Pertussis) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3147  | Medication Received (VZ) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3218  | Medication Treatment (TB) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3311  | Medication Prophylaxis (Malaria) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3312  | Medication Treatment (Malaria) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7055  | Antituberculosis Drugs (TB) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7103  | VPD Laboratory Coded Observation |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7194  | Drugs Used (STD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7475  | Epidural/Spinal Anesthesia - Medication (NCHS) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7539  | Medication Treatment (Babesiosis) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7619  | Antibiotics (FDD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7620  | Antacids (FDD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7635  | Medication Administered (FDD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7693  | Antibiotic Received (RIBD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7700  | AR Agent (RIBD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7759  | Medication (TB) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7834  | Medication Received (TBRD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7839  | Medication Received (Lyme) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7923  | Medication Treatment (STD) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7954  | Medication Administered (Hansen) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7961  | Medication (Leptospirosis) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7963  | Medication Administered (Anthrax) |
http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7972  | Medication (Brucellosis) |
http://fhir.org/guides/argonaut/ValueSet/medication-codes  | Medication Clinical Drug (RxNorm) |
http://fhir.org/guides/argonaut/ValueSet/substance-rxnorm  | DAF Substance RxNorm Codes |
http://capable-project.eu/data/fhir/ValueSet/medical-prescriptions  | Medical prescriptions |
http://hl7.org/fhir/uv/ips/ValueSet/medication-example-uv-ips  | Medications (example) - IPS |
http://hl7.org/fhir/ValueSet/dataelement-sdcobjectclass  | DataElement SDC Object Class |
http://hl7.org/fhir/ValueSet/dataelement-sdcobjectclassproperty  | DataElement SDC Object Class Property |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.1.999.3  | selected first line medications for pain control |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.11.1.999.3  | selected muscle relaxants for pain control |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.12.1.999.3  | Selected topical agents for pain control |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.1.999.2  | selected non opioids for moderate to severe pain |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.11.1.999.2  | Selected opioids for moderate to severe pain |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.3.1  | Opioids used for pain control |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.3.2  | All prescribable opioids used for pain control including Inactive Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.251  | Cerumenolytics |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.11.1.999.319  | Intranasal Antihistamines |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.12.1.999.320  | Mast Cell Stabilizers |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.13.1.999.321  | Ophthalmic Antihistamines |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.11.1.999.315  | Intranasal Corticosteroids |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35292.1.1.999.287  | Oral Second Generation and Less Sedating Antihistamines |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35464.1.1.999.266  | Leukotriene antagonist |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.12.37641.1.1.999.653  | Fidaxomicin |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.12.37696.1.1.999.654  | Proton Pump Inhibitors not including for H. pylori treatment |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38256.1.1.999.662  | Metronidazole Systemic |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38266.1.1.999.663  | Vancomycin non injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.658  | Antiperistaltic agents to avoid in C. diff |
http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.734  | Systemic Antimicrobial Medications not used for CDI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.1  | Substance Reactant for Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.2  | Clinical Substance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.4  | Medication Clinical Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.5  | Medication Clinical Brand specific Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.7  | Clinical Drug Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.8  | Vaccine Clinical Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.16  | Low Intensity Statin Therapy/Branded |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.17  | Moderate Intensity Statin Therapy/Branded |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.18  | High Intensity Statin Therapy/Branded |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.26  | Nonopioid pain medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.303  | Statin Combinations |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.313  | Statin Allergen Grouping |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.319  | Steward Transfer Test |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.320  | Opioids ATCPROD N02A |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.34  | Opioid pain medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.42  | Naloxone and Nalmefene medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.43  | Benzodiazepine medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.44  | Stool softeners and laxatives |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.54  | Adjuvant pain medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.558  | Acute Cluster Headache Medication (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.559  | Long Term Preventive Medication for Cluster Headache |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.561  | Oral Steroid for Cluster Headache |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.569  | Migraine Preventive Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.601  | Acute Migraine Attack Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.605  | NSAID OTC Migraine Attack Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.643  | Antiplatelets |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.644  | Anticoagulants |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.645  | Statin Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.651  | Galcanezumab (RxNorm) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.652  | Lithium (RxNorm) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.653  | Verapamil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.654  | Long term preventive medications for cluster headache |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.655  | Short term preventive medication for cluster headache |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.656  | Zolmitriptan |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.657  | Sumatriptan |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.658  | Dihydroergotamine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.659  | Acute cluster headache medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.39  | Low Dose Unfractionated Heparin for VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.41  | Glycoprotein IIb IIIa Inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.55  | Oxytocin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.56  | Dinoprostone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.241  | Schedule II, III and IV Opioid Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.269  | Medications for Opioid Use Disorder (MOUD) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.107  | Low Intensity Statin Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.543  | Bevacizumab injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.544  | Ranibizumab injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.545  | Aflibercept injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.557  | Corticosteroids for Injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.582  | Corticosteroids for Injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.97  | High Intensity Statin Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.98  | Moderate Intensity Statin Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1072.34  | Primidone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.146  | Long Acting Muscarinic Antagonists (LAMA) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.168  | medications_COPD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.186  | Beta blockers GDMT for heart failure |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.189  | SGLT2i |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.238  | MRA mineralocorticoid receptor antagonists |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.369  | Candesartan |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.377  | Valsartan |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.412  | Statin Moderate Intensity |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.438  | medications_T2DM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.45  | ACE inhibitor allergy/intolerance codes |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.473  | Tetanus toxoid, diphtheria (Td) Vaccine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.48  | ACE inhibitor allergy/intolerance codes |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.527  | OCS_Prednisone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.528  | High Dose Non Combo ICS Adult |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.529  | Medium Dose Non Combo Asthma ICS Adult |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.530  | Low Dose Non Combo ICS |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.531  | Anti IgE Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.532  | IL5 Antagonists |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.533  | Mast cell stabilizers for asthma |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.552  | Triptans |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.553  | CGRP receptor antagonists |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.554  | Ditans |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.555  | Ergots |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.556  | Migraine specific NSAIDs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.557  | OTC migraine analgesics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.558  | Butalbital analgesics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.559  | medications_migraine_acute |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.565  | Triptan Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.569  | Allergen Immunotherapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.578  | PIM_Schedule V |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.580  | PIM_Acarbose |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.581  | PIM_Avandamet |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.582  | PIM_Dulaglutide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.583  | PIM_Glimepiride |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.585  | PIM_Glucophage |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.587  | PIM_Glucovance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.588  | Glyburide PIM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.590  | Alpha glucosidase inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.595  | ICS Low |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.596  | ICS Medium |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.597  | ICS High |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.598  | Low Dose ICS Formoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.604  | PIM_Glyburide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.605  | PIM_Pioglitazone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.606  | PIM_Semaglutide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.607  | PIM_Linagliptin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.609  | Macrolide_Azithromycin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.61  | Secondary antihypertensives |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.610  | Long Acting Beta Agonists (LABA) Non_Formoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.615  | medications_Asthma |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.617  | HighICS_LABA_NonFormoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.619  | ICS_LABA_LAMA |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.620  | Low Dose ICS_LABA_Non Formoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.621  | Medium ICS_LABA Non Formoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.642  | T2DM_Medications Allergy RXNORM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.646  | T2DM_Medication Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.647  | Statins Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.649  | ACE Inhibitors Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.650  | ARB Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.652  | Long Acting Muscarinic Antagonists (LAMA) Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.653  | Long Acting Beta Agonists (LABA) Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.654  | BetaBlocker NonCS Secondary Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.656  | Mineralocorticoid receptor antagonists (MRA) Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.657  | Eplerenone Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.658  | Spironolactone Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.659  | SGLT2i Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.660  | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.661  | Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.665  | Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.666  | Human Papillomavirus (HPV) vaccine Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.667  | Herpes Zoster Vaccine Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.670  | Pneumococcal Vaccine Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.671  | Inhaled Corticosteroids(ICS) Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.672  | LABA(Formoterol only) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.674  | PIM_Tirzepatide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.675  | GLP1RA Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.677  | PIM_H2_Antagonists |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.678  | SGLT2i DM CKD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.679  | SGLT2i DM ASCVD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.680  | GLP1RA DM ASCVD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.683  | PIM_Allopurinol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.684  | GlumetzaSubstitution |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.685  | MetforminER500mg |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.686  | PIM_Metformin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.687  | PIM_Glipizide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.689  | PIM_Glipizide_Glyburide_Glimepiride |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.690  | PIM_Insulin_Meglitinides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.691  | PIM_Glyxambi |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.692  | PIM_Farxiga |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.693  | PIM_Invokana |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.694  | PIM_Jardiance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.695  | PIM_Invokana_Jardiance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.696  | Reclast |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.697  | LAMA_LABA Combination 1 Inhaler |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.698  | PIM_Contraceptives |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.699  | Selected Oral Antiemetics for Migraine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.702  | PIM_SSRIs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.703  | PIM_SNRIs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.704  | PIM_NRIs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.705  | PIM_TCAs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.706  | PIM_Citalopram |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.707  | PIM_Hydroxyzine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.708  | PIM_Buspirone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.709  | PIM_Bupropion |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.710  | PIM_Mirtazapine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.711  | PIM_Trazodone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.714  | PIM_Gabapentin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.715  | PIM_Allergy_Nasal_Sprays |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.716  | PIM_Allergy_Oral_Meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.717  | PIM_Allergy_Nasal_Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.719  | OCS_Prednisolone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.72  | Inhaled corticosteroids (IC) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.720  | COPD_Ofloxacin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.721  | COPD_Ciprofloxacin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.722  | COPD_Doxycycline |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.724  | Macrolides Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.728  | Tetracycline Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.730  | Fluoroquinolone Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.731  | Penicillin Allergy RXNORM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.733  | Penicillin Allergy Intolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.734  | PIM_Metformin_Single_Ingredient_Only |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.735  | PIM_Metformin_Combo_Ingredient_Only |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.779  | PIM_Potassium_Supplements |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.780  | PIM_PPIs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.781  | PIM_Migraine_Medications_Abortive |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.782  | PIM_Migraine_Medications_Preventive |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.783  | PIM_Bisphosphonates |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.784  | PIM_BPH_Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.785  | PIM_Thyroid_Replacement_Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.786  | PIM_Overactive_Bladder_Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.787  | PIM_Topical_Acne_Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.788  | PIM_Antidepressant_Anxiolytic_Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.823  | Aminoglycosides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.824  | Carbapenems |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.826  | Monobactams |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.827  | Penicillins |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.828  | Antimycobacterials |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.829  | Beta_lactamase |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.830  | Cyclic lipopeptides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.831  | Lincosamides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.832  | Macrolides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.833  | Amphenicol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.834  | Oxazolidinones |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.835  | Fluoroquinolones |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.836  | Sulfonamides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.837  | Tetracyclines |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.838  | Phosphonics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.839  | Pleuromutilin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.840  | Streptogramins |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.841  | Lipoglycopeptides |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.842  | Nitroimidazoles |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.843  | PIM_Hyd_Bus_Mir_Tra |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.844  | Nitrofurans |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.845  | Rifamycins |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.846  | Glycylcycline |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.847  | Pyrimidines |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.849  | Antibiotics oral and parenteral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.85  | PCSK9i |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.850  | Medications_hyperkalemia |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.855  | Medications_Chronic Hyperkalemia |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.858  | PIM_Alpha_Blockers_2 |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.870  | PIM_Triptans |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.871  | ICS_SABA Reliever |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.873  | PIM_Asthma_COPD_Meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.876  | Alpha Glucosidase AllergyIntolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.883  | DPP4i AllergyIntolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.890  | Meglitinide AllergyIntolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.891  | Sulfonylurea AllergyIntolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.895  | Thiazolidinedione AllergyIntolerance |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.896  | PIM_Beta_Blockers |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.897  | PIM_CCB_DHPs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.898  | PIM_Loop_Diuretics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.899  | PIM_Inhaled_Corticosteroids_(ICS) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.900  | PIM_Leukotrienes |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.901  | OIA_Asthma_COPD_Meds_Inhalers |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.902  | OIA_Asthma_COPD_Meds_Nebulizers |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.903  | OIA_Asthma_COPD_Meds_Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.904  | OIA_GLP1_Injectables |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.905  | OIA_Insulin_Injectables |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.906  | OIA_Oral_Hypoglycemics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.907  | OIA_DM1_DM2_Meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.908  | Medium Dose ICS Formoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.909  | High Dose ICS Formoterol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.926  | Canagliflozin meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.927  | Empagliflozin meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.928  | Dapagliflozin meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.929  | Ertugliflozin meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.930  | Dulaglutide meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.931  | Liraglutide meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.932  | Semaglutide SC meds |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.933  | T2DM meds benefitting ASCVD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.934  | T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/min |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.935  | T2DM meds benefitting CKD stage 5 |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.936  | T2DM meds benefitting HF with eGFR >= 20 mL/min |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.944  | OIA_Bisoprolol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.947  | OIA_Antihypertensive_Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.959  | ACEi for HFrEF |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.960  | ARB for HFrEF |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.961  | OIA_AntiHTN_Meds_Inclusion_List |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.962  | OIA_Thiazide_Diuretics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.42  | Statin Allergen |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.50  | Rivaroxaban for VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.51  | Prasugrel |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.52  | Pharmacological Contraindications For Antithrombotic Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.61  | Antithrombotic Therapy Antiplatelet |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.62  | Antithrombotic Therapy for Ischemic Stroke |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.146  | Buprenorphine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.166  | Codeine Schedule II and III |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.167  | Alfentanil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.168  | Remifentanil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.169  | Sufentanil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.151  | Cisplatin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.154  | Gemcitabine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.155  | Docetaxel |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.165  | Carboplatin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.166  | Paclitaxel |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.168  | Doxorubicin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.169  | Irinotecan Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.179  | Bevacizumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.181  | Methotrexate |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.196  | Ixabepilone Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.197  | Goserelin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.200  | Epirubicin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.204  | Letrozole |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.206  | Exemestane |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.209  | Fluorouracil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.210  | Capecitabine Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222  | Aprepitant Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.223  | Fosaprepitant Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.257  | Colorectal Cancer Chemotherapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.332  | Daunorubicin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.449  | Opioids |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.492  | Pharmacological interventions for depression |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560  | Rolapitant Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602  | Neurokinin 1 Receptor Antagonist |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.604  | Serotonin Receptor Antagonist |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.61  | Cetuximab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.1  | Schedule IV Benzodiazepines |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.26  | C2S HIV/AIDS Information Sensitivity |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.3  | C2S Alcohol Use Disorders |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.35  | C2S Mental Health Disorders |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.52  | C2S Tobacco Use Disorders |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.58  | C2S Sensitive Categories |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1078  | Opioid Overdose and Poisoning (Naloxone) (RxNorm) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1594  | HIV Infection (ARV Nucleoside Reverse Transcriptase Inhibitors [NRTIs]) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1595  | HIV Infection (ARV Non nucleoside Reverse Transcriptase Inhibitors [NNRTIs]) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1597  | HIV Infection (ARV Combination Treatment for HIV) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1598  | HIV Infection (ARV Protease Inhibitors [PIs]) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1600  | HIV Infection (ARV Integrase Strand Transfer Inhibitors [INSTIs]) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1618  | Smallpox Vaccine (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1634  | Sofosbuvir Velpatasvir Combination (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1912  | Penicillin G [Aqueous Crystalline] [Injectable] (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1913  | Penicillin G [Procaine] [Injectable] (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2142  | Tuberculosis (Linezolid) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2143  | Tuberculosis (Pretomanid) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2144  | Tuberculosis (Bedaquiline) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2362  | Tuberculosis (Ethambutol) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2363  | Tuberculosis (Isoniazid [INH]) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2364  | Tuberculosis (Pyrazinamide [PZA]) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2365  | Tuberculosis (Rifabutin) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2366  | Tuberculosis (Rifampin) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2367  | Tuberculosis (Rifapentine) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.741  | Hepatitis B Immune Globulin (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.844  | Tuberculosis (Second Line Drugs for Treatment) (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.991  | Rifampin (RXNORM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.130  | Anticoagulants for VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.131  | Anticoagulants for Indications Other than VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.32  | Immunosuppressive Drugs for Urology Care |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.4  | BCG Bacillus Calmette Guerin, Tice |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.48  | Androgen deprivation therapy for Urology Care |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.5  | BCG Bacillus Calmette Guerin, Connaught |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.52  | BCG Bacillus Calmette Guerin for Urology Care |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.60  | Chemotherapy Agents for Advanced Cancer |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.43  | Analgesics for Acute Pain |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.57  | Aldosterone Receptor Blocker for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.58  | Alpha Blocker for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.59  | Angiotensin Converting Enzyme Inhibitor for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.60  | Angiotensin II Receptor Blocker for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.61  | Beta Blocker for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.62  | Calcium Channel Blocker Dihydropyridine for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.63  | Calcium Channel Blocker Non Dihydropyridine for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.64  | Central Acting for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.65  | Direct Renin Inhibitor for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.66  | Loop Diuretic for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.67  | Neuronal Blocking Agent for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.68  | Potassium Sparing Diuretic for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.69  | Thiazide Diuretic for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.70  | Vasodilator for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.73  | Analgesics for Acute Pain (Oral Route) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.74  | Analgesics for Acute Pain (Parenteral Route) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.75  | Analgesics for Acute Pain (Non Oral Enteral/Mucosal Routes) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.77  | Antihypertensive Medication Classes |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.129  | Contraceptive Ring RXNORM Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.130  | Contraceptive Implants RXNORM Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.131  | Injectable Contraceptive RXNORM Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.132  | Oral Contraceptive Pills RXNORM Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.76  | Contraceptive Patch RXNORM Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.85  | Intrauterine Devices RXNORM Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.4  | Thrombolytic medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.1  | Ezetimibe Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.10  | Antihypertensive Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.139  | AHA GWTG Anti Obesity Pharmacotherapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.16  | Antihypertensive Fixed Dose Combination Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.2  | PCSK9 Inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.20  | CCB and Thiazide and Thiazide Like Diuretics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.27  | ARNI Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.29  | MRA Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.30  | SGLT2 Inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.35  | Aspirin or Clopidogrel |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43  | SGLT2 Ingredients |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.44  | MRA Ingredients |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.72  | ARNI Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.90  | Non Steroidal Mineralcorticoid Receptor Antagonist |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.91  | Glucagon like peptide 1 medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.1  | Common drug substances for allergy and intolerance documentation |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.7  | Common substances for allergy and intolerance documentation |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.8  | Common substances for allergy and intolerance documentation including refutations |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.58  | Diabetes Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.76  | Fidaxomicin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.77  | Vancomycin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.78  | Metronidazole |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.79  | Fidaxomicin, Vancomycin, and Metronidazole |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.85  | Baloxavir |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.86  | Peramivir |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.87  | Zanamivir |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.90  | NHSN LTC AU Antimicrobial Agents |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1354  | Cefixime preparations for oral administration |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1370  | Beta lactam ingredients for allergy determination RXNORM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.158  | Multiple Myeloma Regimen Drugs |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226  | Opioids, All |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.393  | Hypoglycemics Severe Hypoglycemia |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394  | Hypoglycemics Treatment Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4436  | Gentamicin medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4437  | Azithromycin medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4448  | Lidocaine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469  | Cabotegravir Injectable Products |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470  | Emtricitabine oral for HIV PrEP |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4502  | Ceftriaxone all code types |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.491  | Medium Dose ICS Formoterol Preparations |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495  | ICS LABA LAMA Preparations |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.93  | CPIC RxNORM abacavir SCDG |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.94  | CPIC RxNORM allopurinol SCDG |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.95  | CPIC RxNORM amitriptyline SCDG |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.96  | CPIC RxNORM atazanavir SCDG |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.97  | CPIC RxNORM atomoxetine SCDG |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.99  | CPIC RxNORM capecitabine SCDG |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.12  | Opioid (Oral Tablets and Patches only) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.19  | Anticoagulant Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.20  | Anticoagulant Medications, Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.21  | Anticoagulant Medications, Injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.29  | Fall Risk Increasing Drugs (FRIDs) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.41  | TricyclicAntidepressants |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.42  | Benzodiazepines |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.43  | LoopDiuretics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.44  | Antiepileptics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.45  | Antipsychotics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.46  | Opioid Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.48  | Anticoagulant Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.50  | Bisphosphonate Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.101  | Local Anesthetics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.102  | Ophthalmic Epinephrines |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.103  | Inhaled Epinephrines |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.104  | Clopidogrels |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.105  | Cytochrome P450 2C19 inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.106  | Cytochrome P450 2C9 inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.107  | Aspirin Ingredient and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.109  | Oral Anticoagulant Ingredients and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.110  | Corticosteroid Ingredients and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.111  | Antidepressant Ingredients and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.112  | PPI and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.113  | Antiplatelet Ingredients and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.114  | NSAIDs Ingredients and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.117  | Clopidogrel Ingredients and Risk of GI Bleeding |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.24  | Oxycodones |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.192  | Immunosuppressive Medication RxNorm |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.193  | Medication Supporting Immunosupressive Medication RxNorm |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.197  | Turalio |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.85  | Insulin Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.176  | Methotrexate Injection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.177  | Mifepristone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.178  | Misoprostol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.179  | Abortion Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.183  | Clomiphene (Selective Estrogen Receptor Modulator / SERM) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.184  | Letrozole (Aromatase inhibitor) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.185  | Infertility, Female Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.209  | Transfeminine Regimens, Antiandrogens |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.210  | Transfeminine Regimens, Estrogens |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.211  | Transfeminine Regimens, GnRH Agonists |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.212  | Transfeminine Regimens, All |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.213  | Transmasculine Regimens, Testosterone, Transdermal |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.214  | Transmasculine Regimens, Testosterone, Parenteral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.215  | Transmasculine Regimens, All |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.264  | Heart Failure (CHF)_RxNorm |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.265  | Heart Failure (CHF)_Clinical Condition Grouping |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.342  | AFib (Atrial Fibrillation)_RxNORM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.344  | AFib (Atrial Fibrillation)_Clinical Condition Grouping |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348  | COVID19 Vaccine_RxNorm |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350  | COVID19 Vaccine_Event Clinical Grouping |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.363  | Statin Use_RxNorm |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.379  | Estrogen Agonists Medications_RXNORM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.18  | Medication Prescribable Brand Name |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.22  | Medicinal Ingredients RXNORM |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119  | Opioid Antagonist |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120  | Opioids |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124  | Immune Modulators |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134  | Central Nervous System Depressants |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163  | Antidepressants |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164  | Antihypertensives |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170  | Diuretics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204  | VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22  | Anticoagulants for All Indications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230  | PO Antibacterials |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231  | Injectable Antifungals |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260  | Rivaroxaban Anticoagulant |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262  | Fondaparinux Anticoagulant |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263  | Dalteparin Anticoagulant |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264  | Heparin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268  | Enoxaparin Anticoagulant |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2  | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3  | Prescribable brand and generic insulins and analogues |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9  | IgE Agonists, prescribable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101  | Systemic Cancer Directed Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104  | Erdafitinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111  | Prior Therapies for Erdafitinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14  | Endocrine Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173  | Non Opioid Analgesics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174  | Adjuvant Analgesics |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179  | Prior Therapies for Osimertinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182  | All Antineoplastic Agents |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207  | Osimertinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208  | Pemetrexed |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219  | Tepotinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230  | All Cancer Directed therapies |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249  | pralsetinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250  | Repotrectinib Value set |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251  | Amivantamab |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252  | Alectinib Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253  | Gemcitabine Drug Value set |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254  | vinorelbine Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275  | tarlatamab dlle |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284  | Binimetinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285  | Encorafenib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292  | Prior therapy for Amivantamab |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293  | ENHERTU Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321  | Prior_Systemic_therapy_Enhertu |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326  | Prior_systemic_therapy_Retevmo |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327  | Selpercatinib (Retevmo) Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341  | Aromatase_Inhibitor therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342  | Capivasertib_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343  | Fulvestrant_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363  | Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364  | Chemotherapy_breast_cancer |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365  | Cyclin_dependent_kinase |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366  | Taxane_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367  | Endocrine_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400  | Fluoropyrimidine_CRC |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401  | Oxaliplatin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402  | Irinotecan_based_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403  | anti_VEGF_therapy_CRC |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404  | anti_EGFR_therapy_CRC |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405  | fruquitinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419  | Adagrasib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420  | cetuximab_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421  | Tamoxifen_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436  | Prior_therapy_Endometrial |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437  | Paclitaxel_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441  | Carboplatin_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442  | Durvalumab_therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.467  | Prior_Systemic_therapy_Repotrectinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.47  | Systemic treatment for endometrial cancer |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.470  | Tamoxifen_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.471  | Toremifene_trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.472  | Fulvestrant_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.473  | Elacestrant |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.474  | Anastrozole_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.475  | Leuprolide_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.476  | Abemaciclib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.477  | Palbociclib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.478  | Ribociclib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.479  | Carboplatin_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.480  | Cisplatin_Trodelvy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.481  | Cyclophosphamide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.482  | Methotrexate |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.483  | Gemcitabine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.484  | Capecitabine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.485  | Eribulin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.486  | Doxorubicin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.487  | Vinorelbine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.488  | Epirubicin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.489  | Ixabepilone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.490  | Olaparib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.491  | Talazoparib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.492  | Entrectinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.493  | larotrectinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.494  | Alpelisib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.495  | Capivasertib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.496  | Pembrolizumab |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.497  | Dostarlimab |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.498  | Selpercatinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.499  | Everolimus |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.500  | Trastuzumab_deruxtecan |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.6  | Orserdu |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.68  | Jemperli |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.71  | Platinum based therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.72  | Prior Therapies for Tucatinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.73  | Tucatinib |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.25  | Antibiotic Usage for CAP Diagnosis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.29  | Broad Spectrum Antibiotics for MDRO |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.8  | Systemic Antimicrobials |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.91  | Rho(D) Immune Globulin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134  | Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.200  | Anticoagulant Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.201  | Antithrombotic Therapy Anticoagulant |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.205  | Direct Thrombin Inhibitor |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.211  | Injectable Factor Xa Inhibitor for VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.218  | Unfractionated Heparin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.219  | Low Molecular Weight Heparin for VTE Prophylaxis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.226  | Thrombolytic tPA Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.232  | Warfarin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.423  | Statin Allergen |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.100  | Injectable Fluorouracil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.101  | Trastuzumab and Biosimilars |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.105  | Long Acting Opioids |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.122  | Carmustine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.123  | Dacarbazine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.124  | Streptozocin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.126  | Alemtuzumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.127  | Azacitidine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.128  | Bendamustine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.129  | Busulfan Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.130  | Temozolomide Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.131  | Thiotepa Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.132  | Oxaliplatin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.133  | Romidepsin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.134  | Trabectedin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135  | Dolasetron Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.136  | Dolasetron Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.137  | Granisetron Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138  | Granisetron Transdermal |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.139  | Granisetron Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.140  | Ondansetron Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.141  | Ondansetron Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.142  | Ifosfamide Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.143  | Arsenic Trioxide Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.144  | Netupitant Palonosetron Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.145  | Fosnetupitant Palonosetron Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.146  | Aprepitant Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.147  | Rolapitant Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.148  | Dexamethasone Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.149  | Dexamethasone Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.151  | Olanzapine Oral |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.152  | Olanzapine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.153  | Idarubicin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.154  | Neurokinin 1 Receptor Antagonist Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.155  | Serotonin Receptor Antagonist Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.156  | Clofarabine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.157  | Belinostat Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.158  | Bortezomib Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.159  | Cabazitaxel Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.160  | Carfilzomib Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.161  | Decitabine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.162  | Elotuzumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.163  | Enfortumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.164  | Eribulin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.165  | Etoposide Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.166  | Inotuzumab Ozogamicin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.167  | Mitoxantrone Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.168  | Moxetumomab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.169  | Necitumumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.170  | Nelarabine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.171  | Temsirolimus Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.172  | Tisagenlecleucel Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.173  | Topotecan Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.178  | Atezolizumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.179  | Avelumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.180  | Bleomycin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.181  | Cemiplimab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.182  | Cladribine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.184  | Durvalumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.185  | Emapalumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.186  | Fludarabine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187  | Ipilimumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188  | Nivolumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189  | Pembrolizumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.190  | Polatuzumab Vedotin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.191  | Pralatrexate Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.192  | Vincristine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.193  | Methotrexate Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.194  | Trastuzumab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.195  | Mitomycin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.196  | Brentuximab Vedotin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.197  | Doxorubicin Pegylated Liposomal Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.198  | Blinatumomab Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.199  | Trastuzumab Emtansine Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.200  | Gemtuzumab Ozogamicin Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.201  | Tagraxofusp Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.202  | Axicabtagene Ciloleucel Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.222  | High Emetic Risk Intravenous Antineoplastic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.223  | Moderate Emetic Risk Intravenous Antineoplastic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.224  | Docetaxel Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.225  | Cyclophosphamide Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226  | LAG 3 Inhibitor |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.200  | Doxorubicin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.201  | Epirubicin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.202  | Capecitabine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.203  | Cyclophosphamide |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.204  | Injectable Fluorouracil |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.205  | Methotrexate |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.206  | Trastuzumab and Biosimilars |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.208  | Carboplatin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.210  | Long Acting Opioids |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.212  | Dexamethasone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.213  | Olanzapine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.228  | Low Emetic Risk Intravenous Antineoplastic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.229  | Minimal Emetic Risk Intravenous Antineoplastic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238  | First Line Drug Therapy for Metastatic Colorectal Cancer |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.242  | High Emetic Risk Intravenous Antineoplastic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.243  | Moderate Emetic Risk Intravenous Antineoplastic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.244  | Anthracycline Injectable |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.245  | Antiemetic Agent |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.11  | Oxycodone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.12  | Oxymorphone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.70  | Morphine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.71  | Methadone Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.72  | Meperidine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.73  | Levorphanol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.74  | Hydromorphone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.75  | Hydrocodone |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.76  | Fentanyl |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.77  | Codeine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.12  | Butorphanol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.13  | Dihydrocodeine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.14  | Nalbuphine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.15  | Opium Combinations |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.16  | Pentazocine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.17  | Tapentadol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.18  | Tramadol |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4019  | Fibrinolytic Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4045  | Oral Anticoagulant Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1043  | Potentially Harmful Antihistamines for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1044  | Reserpine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1045  | Reserpine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1049  | Potentially Harmful Antiparkinsonian Agents for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1050  | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1051  | Dipyridamole Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1053  | Nifedipine Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1054  | Potentially Harmful Antidepressants for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1055  | Potentially Harmful Barbiturates for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1057  | Meprobamate Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1058  | Potentially Harmful Estrogens for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1059  | Potentially Harmful Sulfonylureas for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1060  | Desiccated Thyroid Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1062  | Potentially Harmful Skeletal Muscle Relaxants for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1063  | Potentially Harmful Pain Medications for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1065  | Digoxin Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1066  | Digoxin Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1067  | Doxepin Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1068  | Doxepin Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1149  | Substance Use Disorder Long Acting Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1150  | Substance Use Disorder Short Acting Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1170  | Atomoxetine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1171  | Clonidine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1172  | Dexmethylphenidate |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1173  | Dextroamphetamine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1174  | Lisdexamfetamine |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1176  | Methylphenidate |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1190  | Antibiotic Medications for Upper Respiratory Infection |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1247  | Megestrol Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1248  | Meperidine Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1249  | Potentially Harmful Antidepressants for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1250  | Potentially Harmful Antihistamines for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1251  | Potentially Harmful Antiparkinsonian Agents for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1252  | Potentially Harmful Barbiturates for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1253  | Potentially Harmful Estrogens for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1254  | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1255  | Potentially Harmful Pain Medications for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1256  | Potentially Harmful Skeletal Muscle Relaxants for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1257  | Potentially Harmful Sulfonylureas for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1258  | Substance Use Disorder Long Acting Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1259  | Substance Use Disorder Short Acting Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1001  | Antibiotic Medications for Pharyngitis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1078  | Nifedipine Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1080  | Contraceptive Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1109  | Meperidine Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1129  | Desiccated Thyroid Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1143  | Isotretinoin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1167  | Dipyridamole Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205  | Leucovorin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1211  | Aspirin and Other Antiplatelets |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1252  | Guanfacine Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1255  | Megestrol Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256  | Meprobamate Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1266  | Aromatase Inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1267  | Glucocorticoids (oral only) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1481  | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1482  | Potentially Harmful Antiinfectives for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1517  | Dementia Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1530  | Antidepressant Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1531  | Potentially Harmful Benzodiazepines for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1532  | Potentially Harmful Antipsychotics for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1001  | Antibiotic Medications for Pharyngitis |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1080  | Contraceptive Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1143  | Isotretinoin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1205  | Leucovorin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1211  | Aspirin and Other Antiplatelets |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1213  | Antidepressant Medication |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1265  | Aromatase Inhibitors |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1266  | Glucocorticoids (oral only) |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1480  | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1481  | Potentially Harmful Antiinfectives for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1510  | Dementia Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1522  | Potentially Harmful Benzodiazepines for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1523  | Potentially Harmful Antipsychotics for Older Adults |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.1577  | Pharmacologic Therapy for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.133  | Beta Blocker Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1342  | Beta Blocker Therapy for LVSD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1921  | Beta Blocker Therapy Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1926  | ACE Inhibitor or ARB or ARNI Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.3000  | Metformin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.39  | ACE Inhibitor or ARB or ARNI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.423  | Tobacco Use Cessation Pharmacotherapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1139  | ACE Inhibitor or ARB or ARNI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1174  | Beta Blocker Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1184  | Beta Blocker Therapy for LVSD |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1190  | Tobacco Use Cessation Pharmacotherapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1489  | ACE Inhibitor or ARB or ARNI Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1493  | Beta Blocker Therapy Ingredient |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1561  | Medications for Above Normal BMI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1562  | Medications for Below Normal BMI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1566  | Adult Depression Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1567  | Adolescent Depression Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572  | High Intensity Statin Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574  | Low Intensity Statin Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575  | Moderate Intensity Statin Therapy |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.3000  | Metformin |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1498  | Medications for Above Normal BMI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1499  | Medications for Below Normal BMI |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1476  | Pharmacologic Therapy for Hypertension |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.469  | Adolescent Depression Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.470  | Adult Depression Medications |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.16  | Medication Brand Name |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.17  | Medication Clinical General Drug |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3183  | NHSNSkinPreparationCode |
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3360  | NHSNAntimicrobialAgentAURPCode |
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.